Dr. Mintz received her PhD from Tel-Aviv University in immunology and cell research. She established and headed the Bioinformatics Unit at Tel-Aviv University. Dr. Mintz was a member of the founding team of Compugen Ltd. As head of the genomics research she established and managed Compugen’s molecular biology lab and bioinformatics unit. She was responsible for converting Compugen’s bioinformatics discoveries into biological entities. Dr. Mintz is a pioneer in the discovery of splice variants and an inventor of more than 30 U.S. and international patents. After leaving Compugen Dr. Mintz founded DiaLean Ltd., a company that develops peptide therapeutics based on novel proteins discovered using proprietary bioinformatics methodologies. Dln-101, DiaLean’s lead molecule, is being developed for the treatment of Parkinson's disease.